Skip to main content
Top
Published in: Current Treatment Options in Gastroenterology 3/2016

01-09-2016 | Intractable Disease in the Elderly: When Conventional Therapy Fails (S Katz, Section Editor)

Management of Inflammatory Bowel Disease in the Elderly

Authors: Elizabeth S. John, MD, Kristina Katz, MD, Mark Saxena, MD, Sita Chokhavatia, MD, Seymour Katz, MD

Published in: Current Treatment Options in Gastroenterology | Issue 3/2016

Login to get access

Opinion Statement

A substantial and growing proportion of patients with inflammatory bowel disease (IBD) are elderly, and these patients require tailored treatment strategies. However, significant challenges exist in the management of this population due to the paucity of data. Establishing the initial diagnosis and assessing the etiology of future symptoms and flares can be challenging as several other prevalent diseases can masquerade as IBD, such as ischemic colitis, diverticular disease, and infectious colitis. Important pharmacologic considerations include reduced glomerular filtration rate and drug-drug interactions in the elderly. No drug therapy is absolutely contraindicated in this population; however, special risk and benefit assessments should be made. Older patients are more susceptible to side effects of steroids such as delirium, fractures, and cataracts. Budesonide can be an appropriate alternative for mild to moderate ulcerative colitis (UC) or Crohn’s disease (CD) as it has limited systemic absorption. Pill size and quantity, nephrotoxicity, and difficulty of administration of rectal preparations should be considered with 5-aminosalicylic (5-ASA) therapy. Biologics are very effective, but modestly increase the risk of infection in a susceptible group. Based on their mechanisms, integrin receptor antagonists (e.g., vedolizumab) may reduce these risks. Use of antibiotics for anorectal or fistulizing CD or pouchitis in UC increases the risk of Clostridium difficile infection. Pre-existing comorbidities, functional status, and nutrition are important indicators of surgical outcomes. Morbidity and mortality are increased among IBD patients undergoing surgery, often due to postoperative complications or sepsis. Elderly adults with IBD, particularly UC, have very high rates of venous thromboembolism (VTE). Colonoscopy appears safe, but the optimal surveillance interval has not been well defined. Should the octogenarian, nonagenarian, and centurion undergo colonoscopy? The length of surveillance should likely account for the individual’s overall life expectancy. Specific health maintenance should emphasize administering non-live vaccines to patients on thiopurines or biologics and regular skin exams for those on thiopurines. Smoking cessation is crucial to overall health and response to medical therapy, even among UC patients. This article will review management of IBD in the elderly.
Literature
1.
go back to reference Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn’s disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci. 2013;58:519–25.CrossRefPubMed Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn’s disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci. 2013;58:519–25.CrossRefPubMed
2.
3.
go back to reference Loftus Jr EV, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. Gut. 2000;46:336–43.CrossRefPubMedPubMedCentral Loftus Jr EV, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. Gut. 2000;46:336–43.CrossRefPubMedPubMedCentral
4.
5.
go back to reference Loftus CG, Loftus Jr EV, Harmsen WS, et al. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflamm Bowel Dis. 2007;13:254–61.CrossRefPubMed Loftus CG, Loftus Jr EV, Harmsen WS, et al. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflamm Bowel Dis. 2007;13:254–61.CrossRefPubMed
6.••
go back to reference Lakatos PL, David G, Pandur T, et al. IBD in the elderly population: results from a population-based study in Western Hungary, 1977-2008. J Crohns Colitis. 2011;5:5–13. This study conducted in Western Hungary investigated the incidence and course of IBD with respect to age. They found that in the 1420 incident patients, the prevalence of IBD in the elderly population was increasing with distinct characteristics of CD and UC in the elderly.CrossRefPubMed Lakatos PL, David G, Pandur T, et al. IBD in the elderly population: results from a population-based study in Western Hungary, 1977-2008. J Crohns Colitis. 2011;5:5–13. This study conducted in Western Hungary investigated the incidence and course of IBD with respect to age. They found that in the 1420 incident patients, the prevalence of IBD in the elderly population was increasing with distinct characteristics of CD and UC in the elderly.CrossRefPubMed
7.••
go back to reference Charpentier C, Salleron J, Savoye G, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 2014;63:423–32. This French based study specifically looked at elderly-onset IBD, and found that the course of IBD is milder in elderly patients, specifically greater than 60 years of age.CrossRefPubMed Charpentier C, Salleron J, Savoye G, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 2014;63:423–32. This French based study specifically looked at elderly-onset IBD, and found that the course of IBD is milder in elderly patients, specifically greater than 60 years of age.CrossRefPubMed
8.
go back to reference Gudsoorkar VS, Abraham B. Inflammatory bowel disease in the elderly: hazards of generalizing the evidence. Pract Gastroenterol. 2015: 26-40. Gudsoorkar VS, Abraham B. Inflammatory bowel disease in the elderly: hazards of generalizing the evidence. Pract Gastroenterol. 2015: 26-40.
9.
go back to reference Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroeneterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501–23.CrossRefPubMed Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroeneterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501–23.CrossRefPubMed
10.
go back to reference Lichenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;104:465–83.CrossRef Lichenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;104:465–83.CrossRef
11.
go back to reference Katz S, Pardi DS. Inflammatory bowel disease of the elderly: frequently asked questions (FAQs). Am J Gastroenterol. 2011;106:1889–97.CrossRefPubMed Katz S, Pardi DS. Inflammatory bowel disease of the elderly: frequently asked questions (FAQs). Am J Gastroenterol. 2011;106:1889–97.CrossRefPubMed
12.
go back to reference Shung DL, Abraham B, Sellin J, Hou JK. Medical and surgical complications of inflammatory bowel disease in the elderly: a systematic review. Dig Dis Sci. 2015;60(5):1132–40.CrossRefPubMed Shung DL, Abraham B, Sellin J, Hou JK. Medical and surgical complications of inflammatory bowel disease in the elderly: a systematic review. Dig Dis Sci. 2015;60(5):1132–40.CrossRefPubMed
13.
go back to reference Fordtran JS. Colitis due to C.diff toxins, underdiagnosed, highly virulent, and nosocomial. Proc (Baylor Univ Med Cent). 2006;19(1):3–12. Fordtran JS. Colitis due to C.diff toxins, underdiagnosed, highly virulent, and nosocomial. Proc (Baylor Univ Med Cent). 2006;19(1):3–12.
14.
go back to reference Collins CE, Ayturk MD, Flahive JM, et al. Epidemiology and outcomes of community-acquired Clostridium difficile infections in medicare beneficiaries. J Am Coll Surg. 2014;218:1141–7.CrossRefPubMedPubMedCentral Collins CE, Ayturk MD, Flahive JM, et al. Epidemiology and outcomes of community-acquired Clostridium difficile infections in medicare beneficiaries. J Am Coll Surg. 2014;218:1141–7.CrossRefPubMedPubMedCentral
15.
go back to reference Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology study. Gastroenterology. 2013;145:158–65.CrossRefPubMed Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology study. Gastroenterology. 2013;145:158–65.CrossRefPubMed
16.
go back to reference Hadithi M, Cazemier M, Meijer GA, et al. Retrospective analysis of old-age colitis in the Dutch inflammatory bowel disease population. World J Gastroenterol. 2008;14:3183–7.CrossRefPubMedPubMedCentral Hadithi M, Cazemier M, Meijer GA, et al. Retrospective analysis of old-age colitis in the Dutch inflammatory bowel disease population. World J Gastroenterol. 2008;14:3183–7.CrossRefPubMedPubMedCentral
17.
18.
go back to reference Taleban S. Challenges in the diagnosis and management of inflammatory bowel disease in the elderly. Curr Treat Options Gastro. 2015;13:275–86.CrossRef Taleban S. Challenges in the diagnosis and management of inflammatory bowel disease in the elderly. Curr Treat Options Gastro. 2015;13:275–86.CrossRef
19.
go back to reference Nilsen T, Sundström J, Lind L, et al. Serum calprotectin levels in elderly males and females without bacterial or viral infections. Clin Biochem. 2014;47:1065–8.CrossRefPubMed Nilsen T, Sundström J, Lind L, et al. Serum calprotectin levels in elderly males and females without bacterial or viral infections. Clin Biochem. 2014;47:1065–8.CrossRefPubMed
20.
go back to reference Joshi S, Lewis SJ, Creanor S, et al. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann Clin Biochem. 2010;47:259–63.CrossRefPubMed Joshi S, Lewis SJ, Creanor S, et al. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann Clin Biochem. 2010;47:259–63.CrossRefPubMed
21.
go back to reference Page MJ, Poritz LS, Kunselman SJ, et al. Factors affecting surgical risk in elderly patients with inflammatory bowel disease. J Gastrointest Surg. 2002;6:606–13.CrossRefPubMed Page MJ, Poritz LS, Kunselman SJ, et al. Factors affecting surgical risk in elderly patients with inflammatory bowel disease. J Gastrointest Surg. 2002;6:606–13.CrossRefPubMed
22.
go back to reference Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Lofland JH. Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey. Dig Dis Sci. 2012;57(12):3080–91.CrossRefPubMed Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Lofland JH. Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey. Dig Dis Sci. 2012;57(12):3080–91.CrossRefPubMed
23.
go back to reference Lexicomp Online®, Hudson, Ohio: Lexi-Comp, Inc.; 2015. Lexicomp Online®, Hudson, Ohio: Lexi-Comp, Inc.; 2015.
25.
go back to reference Ananthakrishnan AN, Binion D. Treatment of ulcerative colitis in the elderly. Dig Dis. 2009;27:327–34.CrossRefPubMed Ananthakrishnan AN, Binion D. Treatment of ulcerative colitis in the elderly. Dig Dis. 2009;27:327–34.CrossRefPubMed
26.
go back to reference Vagianos K, Clara I, Carr R, et al. What are adults with inflammatory nowel disease (IBD) eating? A closer look at the dietary habits of a population-based Canadian IBD cohort. JPEN J Parenter Enteral Nutr. pii 10.1177/0148607114549254 Vagianos K, Clara I, Carr R, et al. What are adults with inflammatory nowel disease (IBD) eating? A closer look at the dietary habits of a population-based Canadian IBD cohort. JPEN J Parenter Enteral Nutr. pii 10.​1177/​0148607114549254​
27.
go back to reference Lee J, Allen R, Ashley S. British Dietetic Association evidence-based guidelines for the dietary management of Crohn’s disease in adults. J Hum Nutr Diet. 27(3): 207-18. Lee J, Allen R, Ashley S. British Dietetic Association evidence-based guidelines for the dietary management of Crohn’s disease in adults. J Hum Nutr Diet. 27(3): 207-18.
28.
go back to reference Martin GS, Tapsell LC, Denmeade S. Relative validity of a diet history interview in an intervention trial manipulating dietary fat in the management of Type II diabetes mellitus. Prev Med. 36(4): 420-8. Martin GS, Tapsell LC, Denmeade S. Relative validity of a diet history interview in an intervention trial manipulating dietary fat in the management of Type II diabetes mellitus. Prev Med. 36(4): 420-8.
29.
go back to reference Pigneur B, Seksik P, Viola S, Viala J, Beaugerie L, Girardet JP, et al. Natural history of Crohn’s disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis. 2010;16:953–61.CrossRefPubMed Pigneur B, Seksik P, Viola S, Viala J, Beaugerie L, Girardet JP, et al. Natural history of Crohn’s disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis. 2010;16:953–61.CrossRefPubMed
30.••
go back to reference Taleban S, Colombel JF, Mohler MJ, Fain MJ. Inflammatory bowel disease and the elderly: a review. J Crohns Colitis. 2015;9(6):507–15. This recent review delineates the growing incidence and prevalence of IBD in the elderly, highlights the different pathophysiologies and clinical manifestations between younger and older patients, and reviews the medical and surgical managements of elderly adults with IBD.CrossRefPubMed Taleban S, Colombel JF, Mohler MJ, Fain MJ. Inflammatory bowel disease and the elderly: a review. J Crohns Colitis. 2015;9(6):507–15. This recent review delineates the growing incidence and prevalence of IBD in the elderly, highlights the different pathophysiologies and clinical manifestations between younger and older patients, and reviews the medical and surgical managements of elderly adults with IBD.CrossRefPubMed
31.
go back to reference Fangbin Z, Xiang G, Minhu C, et al. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease? Ther Drug Monit. 2012;34:695–701.CrossRefPubMed Fangbin Z, Xiang G, Minhu C, et al. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease? Ther Drug Monit. 2012;34:695–701.CrossRefPubMed
32.
go back to reference Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19:893–9.CrossRefPubMed Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19:893–9.CrossRefPubMed
33.
go back to reference Juneja M, Maidoo L, Schwartz MB, Barrie 3rd A, Regueiro M, Dunn M, et al. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig Dis Sci. 2012;57:2408–15.CrossRefPubMed Juneja M, Maidoo L, Schwartz MB, Barrie 3rd A, Regueiro M, Dunn M, et al. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig Dis Sci. 2012;57:2408–15.CrossRefPubMed
34.
go back to reference Min H, Montecino-Rodriguez E, Dorshkind K. Effects of aging on early B- and T-cell development. Immunol Rev. 2005;205:7–17.CrossRefPubMed Min H, Montecino-Rodriguez E, Dorshkind K. Effects of aging on early B- and T-cell development. Immunol Rev. 2005;205:7–17.CrossRefPubMed
35.
go back to reference D-Haens G, Verstraete A, Cheyns K, et al. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn’s disease. Aliment Pharmacol Ther. 1998;129:716–8. D-Haens G, Verstraete A, Cheyns K, et al. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn’s disease. Aliment Pharmacol Ther. 1998;129:716–8.
36.
go back to reference Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med. 1994;331:842–5.CrossRefPubMed Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med. 1994;331:842–5.CrossRefPubMed
37.
go back to reference Ramos MI, Allen LH, Mungas DM, et al. Low folate status is associated with impaired cognitive function and dementia in the Sacramento Area Latino Study on Ageing. Am J Clin Nutr. 2005;82:1346–52.PubMed Ramos MI, Allen LH, Mungas DM, et al. Low folate status is associated with impaired cognitive function and dementia in the Sacramento Area Latino Study on Ageing. Am J Clin Nutr. 2005;82:1346–52.PubMed
38.
go back to reference Shea B, Swinden MV, Tanjon Ghogomu E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate fur rheumatoid arthritis. J Rheumatol. 2014;109:163–9. Shea B, Swinden MV, Tanjon Ghogomu E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate fur rheumatoid arthritis. J Rheumatol. 2014;109:163–9.
39.
go back to reference Bertino J, Cleary J, Ortiz T, Lane A, Supko JG, Ryan D. Cytotoxic agents. Goodman and Gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill Global Education Holdings; 2011. Bertino J, Cleary J, Ortiz T, Lane A, Supko JG, Ryan D. Cytotoxic agents. Goodman and Gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill Global Education Holdings; 2011.
40.
go back to reference Bannwarth B, Péhourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet. 1996;30(3):194–210.CrossRefPubMed Bannwarth B, Péhourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet. 1996;30(3):194–210.CrossRefPubMed
41.
go back to reference Crom WR, Evan WE. Methotrexate. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. New York: Lippincott Williams & Wilkins; 1992. Crom WR, Evan WE. Methotrexate. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. New York: Lippincott Williams & Wilkins; 1992.
42.
go back to reference Cudmore J, Seftel M, Sisler J, Zarychanski R. Methotrexate and trimethoprim-sulfamethoxazole toxicity from this combination continues to occur. Can Fam Physician. 2014;60(1):53–6.PubMedPubMedCentral Cudmore J, Seftel M, Sisler J, Zarychanski R. Methotrexate and trimethoprim-sulfamethoxazole toxicity from this combination continues to occur. Can Fam Physician. 2014;60(1):53–6.PubMedPubMedCentral
43.
go back to reference Bourre-Tessier J, Haraoui B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J Rheumatol. 2010;37:1416–21.CrossRefPubMed Bourre-Tessier J, Haraoui B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J Rheumatol. 2010;37:1416–21.CrossRefPubMed
44.
go back to reference Turrentine FE, Wang H, Simpson VB, et al. Surgical risk factors, morbidity, and mortality in elderly patients. J Am Coll Surg. 2006;203:865–77.CrossRefPubMed Turrentine FE, Wang H, Simpson VB, et al. Surgical risk factors, morbidity, and mortality in elderly patients. J Am Coll Surg. 2006;203:865–77.CrossRefPubMed
45.
go back to reference Teml A, Schaeffeler E, Herrlinger KR, et al. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet. 2007;46:187–208.CrossRefPubMed Teml A, Schaeffeler E, Herrlinger KR, et al. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet. 2007;46:187–208.CrossRefPubMed
46.
go back to reference Hoentjen F, Seinen ML, Hanauer SB, et al. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:363–9.CrossRefPubMed Hoentjen F, Seinen ML, Hanauer SB, et al. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:363–9.CrossRefPubMed
47.
go back to reference Irving PM, Shanahan F, Rampton DS. Drug interactions in inflammatory bowel disease. Am J Gastroenterol. 2008;103:207–19.CrossRefPubMed Irving PM, Shanahan F, Rampton DS. Drug interactions in inflammatory bowel disease. Am J Gastroenterol. 2008;103:207–19.CrossRefPubMed
48.
go back to reference Khan N, Abbas AM, Lichtenstein GR, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology. 2013; 145-1007-15. Khan N, Abbas AM, Lichtenstein GR, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology. 2013; 145-1007-15.
49.
go back to reference Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874–81.CrossRefPubMedPubMedCentral Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874–81.CrossRefPubMedPubMedCentral
50.
go back to reference Mehmood F, Wysocki J, Serper M, et al. Efficacy and safety of thiopurine therapy in patients with elderly onset ulcerative colitis. Aliment Pharma Ther. 2015. Mehmood F, Wysocki J, Serper M, et al. Efficacy and safety of thiopurine therapy in patients with elderly onset ulcerative colitis. Aliment Pharma Ther. 2015.
51.
go back to reference Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:390–9.CrossRefPubMedPubMedCentral Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:390–9.CrossRefPubMedPubMedCentral
52.
go back to reference Kopylov U, Vutcovici M, Kezouh A, Seidman E, Bitton A, Afif W. Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a Quebec Claims Database Study. Inflamm Bowel Dis. 2015. Kopylov U, Vutcovici M, Kezouh A, Seidman E, Bitton A, Afif W. Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a Quebec Claims Database Study. Inflamm Bowel Dis. 2015.
53.
go back to reference Sokol H, Beaugerie L, Maynadie M, et al. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2063–71.CrossRefPubMed Sokol H, Beaugerie L, Maynadie M, et al. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2063–71.CrossRefPubMed
54.
go back to reference Jeuring S, Van den Heuvel T, Zeegers M, et al. Is elderly-onset ulcerative colitis a different entity?—natural disease course and treatment response compared to adult-onset disease in the population-based IBD-SL cohort. J Crohns Colitis. 2014;8 Suppl 1:S3–4.CrossRef Jeuring S, Van den Heuvel T, Zeegers M, et al. Is elderly-onset ulcerative colitis a different entity?—natural disease course and treatment response compared to adult-onset disease in the population-based IBD-SL cohort. J Crohns Colitis. 2014;8 Suppl 1:S3–4.CrossRef
55.
go back to reference Ariyaratnam J, Subramanian V. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis. Am J Gastroenterol. 2014;109:163–9.CrossRefPubMed Ariyaratnam J, Subramanian V. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis. Am J Gastroenterol. 2014;109:163–9.CrossRefPubMed
56.
go back to reference Chaparro M, Ordas I, Cabre E, et al. Safety of thiopurine therapy in inflammatory bowel disease; long-term follow up study of 3931 patients. Inflamm Bowel Dis. 2013;19:1404–10.CrossRefPubMed Chaparro M, Ordas I, Cabre E, et al. Safety of thiopurine therapy in inflammatory bowel disease; long-term follow up study of 3931 patients. Inflamm Bowel Dis. 2013;19:1404–10.CrossRefPubMed
57.
go back to reference Pardi DS, Loftus Jr EV, Camilleri M. Treatment of inflammatory bowel disease in the elderly: an update. Drugs Aging. 2002;19(5):355–63.CrossRefPubMed Pardi DS, Loftus Jr EV, Camilleri M. Treatment of inflammatory bowel disease in the elderly: an update. Drugs Aging. 2002;19(5):355–63.CrossRefPubMed
58.
go back to reference Kornbluth A, Present DH, Lichtiger S, Hanauer S. Cyclosporin for severe ulcerative colitis: a user’s guide. Am J Gastroenterol. 1997;92(9):1424–8.PubMed Kornbluth A, Present DH, Lichtiger S, Hanauer S. Cyclosporin for severe ulcerative colitis: a user’s guide. Am J Gastroenterol. 1997;92(9):1424–8.PubMed
59.
go back to reference Lobaton T, Ferrante M, Rutgeerts P, Ballet V, Van Assche G, Vermeire S. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2015. Lobaton T, Ferrante M, Rutgeerts P, Ballet V, Van Assche G, Vermeire S. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2015.
60.
go back to reference Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:123–8.CrossRefPubMed Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:123–8.CrossRefPubMed
61.
go back to reference Desai A, Zator ZA, de Silva P, Nguyen DD, Korzenik J, Yajnik V, et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(2):309–15.CrossRefPubMedPubMedCentral Desai A, Zator ZA, de Silva P, Nguyen DD, Korzenik J, Yajnik V, et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(2):309–15.CrossRefPubMedPubMedCentral
62.
go back to reference Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009;30(3):210–26.CrossRefPubMed Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009;30(3):210–26.CrossRefPubMed
63.
go back to reference Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95.CrossRefPubMed Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95.CrossRefPubMed
64.
go back to reference Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut. 2009;58(4):492–500.CrossRefPubMed Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut. 2009;58(4):492–500.CrossRefPubMed
65.
go back to reference Clarke K, Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis. 2012;18:174–9.CrossRefPubMed Clarke K, Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis. 2012;18:174–9.CrossRefPubMed
66.
go back to reference Van Assche G, Magdelaine-Beuzelin C, D’Haens G, et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134:1861–8.CrossRefPubMed Van Assche G, Magdelaine-Beuzelin C, D’Haens G, et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134:1861–8.CrossRefPubMed
67.
go back to reference Cottone M, Kohn A, Daperno M, Armuzzi A, Guidi L, D’Inca R, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30–5.CrossRefPubMed Cottone M, Kohn A, Daperno M, Armuzzi A, Guidi L, D’Inca R, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30–5.CrossRefPubMed
68.
go back to reference Byun JM, Lee CK, Rhee SY, et al. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-alpha inhibitor. Scand J Gastroenterol. 2015;50:312–20.CrossRefPubMed Byun JM, Lee CK, Rhee SY, et al. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-alpha inhibitor. Scand J Gastroenterol. 2015;50:312–20.CrossRefPubMed
69.
go back to reference Kim M, Dam A, Green J. Common GI drug interactions in the elderly. Curr Treat Options Gastroenterol. 2014;12:292–309.CrossRefPubMed Kim M, Dam A, Green J. Common GI drug interactions in the elderly. Curr Treat Options Gastroenterol. 2014;12:292–309.CrossRefPubMed
70.
go back to reference Dulai PS, Siegel CA. The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease. Gastroenterol Clin N Am. 2014;43(3):525–41.CrossRef Dulai PS, Siegel CA. The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease. Gastroenterol Clin N Am. 2014;43(3):525–41.CrossRef
71.
go back to reference Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systemic review and meta-analysis. Ann Rheum Dis. 2011;70:1895–904.CrossRefPubMed Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systemic review and meta-analysis. Ann Rheum Dis. 2011;70:1895–904.CrossRefPubMed
72.
go back to reference Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohn’s disease: results from the TREAT registry. Am J Gastroenterol. 2014;109(2):212–23.CrossRefPubMed Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohn’s disease: results from the TREAT registry. Am J Gastroenterol. 2014;109(2):212–23.CrossRefPubMed
73.
go back to reference Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121–5.CrossRefPubMedPubMedCentral Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121–5.CrossRefPubMedPubMedCentral
74.
go back to reference Axelrad J, Bernheim O, Colombel JF, Malerba S, Ananthakrishnan A, Yajnik V, et al. Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14(1):58–64.CrossRefPubMed Axelrad J, Bernheim O, Colombel JF, Malerba S, Ananthakrishnan A, Yajnik V, et al. Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14(1):58–64.CrossRefPubMed
75.
go back to reference Nyboe A, Pasternak B, Basit S, Andersson M, Svanström H, Caspersen S, et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014;311(23):2406–13.CrossRef Nyboe A, Pasternak B, Basit S, Andersson M, Svanström H, Caspersen S, et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014;311(23):2406–13.CrossRef
76.
go back to reference Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–25.CrossRefPubMed Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–25.CrossRefPubMed
77.
go back to reference Khanna D, McMahon M, Furst DE. Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here? Arthritis Rheum. 2004;50(4):1040–50.CrossRefPubMed Khanna D, McMahon M, Furst DE. Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here? Arthritis Rheum. 2004;50(4):1040–50.CrossRefPubMed
78.
79.
go back to reference Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–21.CrossRefPubMed Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–21.CrossRefPubMed
80.
go back to reference Feagan BG, Rutgerrts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, axler J, Kim HF, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A. Vedlizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013; 369-699-710. Feagan BG, Rutgerrts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, axler J, Kim HF, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A. Vedlizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013; 369-699-710.
81.
go back to reference Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353:1912–25.CrossRefPubMed Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353:1912–25.CrossRefPubMed
82.
go back to reference Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology. 2007;132:1672–83.CrossRefPubMed Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology. 2007;132:1672–83.CrossRefPubMed
83.
go back to reference Yajnik V, Khan N, Dubinsky M, et al. Efficacy and safety of vedolizumab with advancing age in patients with ulcerative colitis: results from the GEMINI I study [poster Sa1274]. Poster presented at: 2015 Digestive Disease Week (DDW); 2015; Washington, DC Yajnik V, Khan N, Dubinsky M, et al. Efficacy and safety of vedolizumab with advancing age in patients with ulcerative colitis: results from the GEMINI I study [poster Sa1274]. Poster presented at: 2015 Digestive Disease Week (DDW); 2015; Washington, DC
84.
go back to reference Yajnik V, Khan N, Dubinsky M, et al. Efficacy and safety of vedolizumab with advancing age in patients with Crohn’s disease: results from the GEMINI 2 study [poster P1764]. Honolulu: Poster presented at: 2015 American College of Gastroenterology Annual Scientific Meeting; 2015. Yajnik V, Khan N, Dubinsky M, et al. Efficacy and safety of vedolizumab with advancing age in patients with Crohn’s disease: results from the GEMINI 2 study [poster P1764]. Honolulu: Poster presented at: 2015 American College of Gastroenterology Annual Scientific Meeting; 2015.
85.
go back to reference Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging. 2010;27:193–209.CrossRefPubMed Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging. 2010;27:193–209.CrossRefPubMed
86.
go back to reference Cios A, Wyska E, Szymura-Oleksiak J, Grodzicki T. Population pharmacokinetic analysis of ciprofloxacin in the elderly patients with lower respiratory tract infections. Exp Gerontol. 2014;57:107–13.CrossRefPubMed Cios A, Wyska E, Szymura-Oleksiak J, Grodzicki T. Population pharmacokinetic analysis of ciprofloxacin in the elderly patients with lower respiratory tract infections. Exp Gerontol. 2014;57:107–13.CrossRefPubMed
87.
go back to reference Frytak S, Moertel CH, Childs DS. Neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med. 1978;88:361–2.CrossRefPubMed Frytak S, Moertel CH, Childs DS. Neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med. 1978;88:361–2.CrossRefPubMed
88.
go back to reference Freeman CD, Klutman NE, Lamp KC. Metronidazole. A therapeutic review and update. Drugs. 1997;54:679–708.CrossRefPubMed Freeman CD, Klutman NE, Lamp KC. Metronidazole. A therapeutic review and update. Drugs. 1997;54:679–708.CrossRefPubMed
89.
go back to reference Kaplan GG et al. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology. 2008;134:680–7.CrossRefPubMed Kaplan GG et al. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology. 2008;134:680–7.CrossRefPubMed
90.
go back to reference Kaplan GG et al. Risk of comorbidities on postoperative outcomes in patients with inflammatory bowel disease. Arch Surg. 2011;146:959–64.CrossRefPubMed Kaplan GG et al. Risk of comorbidities on postoperative outcomes in patients with inflammatory bowel disease. Arch Surg. 2011;146:959–64.CrossRefPubMed
91.
go back to reference Ha C, Payless T, Wick E. Increased incidence of postoperative complications in older inflammatory bowel disease patients having intestinal surgery [abstract 104]. Gastroenterology. 2012;142 Suppl 1:S245. Ha C, Payless T, Wick E. Increased incidence of postoperative complications in older inflammatory bowel disease patients having intestinal surgery [abstract 104]. Gastroenterology. 2012;142 Suppl 1:S245.
92.
go back to reference Ha CY, Katz S. Clinical outcomes and management of inflammatory bowel disease in the older patient. Curr Gastroenterology Rep. 2013;15:310.CrossRef Ha CY, Katz S. Clinical outcomes and management of inflammatory bowel disease in the older patient. Curr Gastroenterology Rep. 2013;15:310.CrossRef
93.
go back to reference Ikeuchi H, Uchino M, Matsuoka H, et al. Prognosis following emergency surgery for ulcerative colitis in elderly patients. Surg Today. 2014;44:39–43.CrossRefPubMed Ikeuchi H, Uchino M, Matsuoka H, et al. Prognosis following emergency surgery for ulcerative colitis in elderly patients. Surg Today. 2014;44:39–43.CrossRefPubMed
94.
go back to reference Blonski W, Lichenstein GR. Survival in elderly patients with ulcerative colitis and colorectal cancer. Dig Dis Sci. 2012;57:1435–8.CrossRefPubMed Blonski W, Lichenstein GR. Survival in elderly patients with ulcerative colitis and colorectal cancer. Dig Dis Sci. 2012;57:1435–8.CrossRefPubMed
95.
go back to reference Gisbert JP, Chaparro M. Systematic review with meta-analysis: inflammatory bowel disease in the elderly. Ailment Pharmacol Ther. 2014;39(5):459–77.CrossRef Gisbert JP, Chaparro M. Systematic review with meta-analysis: inflammatory bowel disease in the elderly. Ailment Pharmacol Ther. 2014;39(5):459–77.CrossRef
96.
go back to reference Duricova D, Burisch J, Jess T, Gower-Rousseau CG, Lakatos PL. Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature. J Crohn’s Colitis. 2014;8:1351–61.CrossRef Duricova D, Burisch J, Jess T, Gower-Rousseau CG, Lakatos PL. Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature. J Crohn’s Colitis. 2014;8:1351–61.CrossRef
97.
go back to reference Wang YR, Cangemi JR, Loftus Jr EV, Picco MF. Rate of early/missed colorectal cancers after colonoscopy in older paitents with or without inflammatory bowel disease in the United States. Am J Gastroenterol. 2013;108:444–9.CrossRefPubMed Wang YR, Cangemi JR, Loftus Jr EV, Picco MF. Rate of early/missed colorectal cancers after colonoscopy in older paitents with or without inflammatory bowel disease in the United States. Am J Gastroenterol. 2013;108:444–9.CrossRefPubMed
98.
go back to reference Terheggen G, Lanyi B, Schanz S, et al. Safety, feasibility, tolerability of ileocolonoscopy in inflammatory bowel disease. Endoscopy. 2008;40:656–63.CrossRefPubMed Terheggen G, Lanyi B, Schanz S, et al. Safety, feasibility, tolerability of ileocolonoscopy in inflammatory bowel disease. Endoscopy. 2008;40:656–63.CrossRefPubMed
99.
go back to reference Warren JL, Klabunde CN, Mariotto AB, et al. Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med. 2009;150:849–57. W152.CrossRefPubMed Warren JL, Klabunde CN, Mariotto AB, et al. Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med. 2009;150:849–57. W152.CrossRefPubMed
100.
go back to reference Arora G, Mannalithara A, Singh G, et al. Risk of perforation from a colonoscopy in adults: a large population-based study. Gastrointest Endosc. 2009;69:654–64.CrossRefPubMed Arora G, Mannalithara A, Singh G, et al. Risk of perforation from a colonoscopy in adults: a large population-based study. Gastrointest Endosc. 2009;69:654–64.CrossRefPubMed
101.
go back to reference Day LW, Kwon A, Inadomi JM, et al. Adverse events in older patients undergoing colonoscopy: a systematic review and meta-analysis. Gastrointest Endosc. 2011;74:885–96.CrossRefPubMedPubMedCentral Day LW, Kwon A, Inadomi JM, et al. Adverse events in older patients undergoing colonoscopy: a systematic review and meta-analysis. Gastrointest Endosc. 2011;74:885–96.CrossRefPubMedPubMedCentral
102.
go back to reference Horton HA, Kim H, Melmed GY. Vaccinations in older adults with gastrointestinal diseases. Clin Geriatr Med. 2014;30(1):17–28.CrossRefPubMed Horton HA, Kim H, Melmed GY. Vaccinations in older adults with gastrointestinal diseases. Clin Geriatr Med. 2014;30(1):17–28.CrossRefPubMed
103.
go back to reference Cheetham TC, Marcy SM, Tseng HF, Sy LS, Liu IL, Bixler F, et al. Risk of herpes zoster and disseminated varicella zoster in patients taking immunosuppressant drugs at the time of zoster vaccination. Mayo Clin Proc. 2015;90(7):865–73.CrossRefPubMed Cheetham TC, Marcy SM, Tseng HF, Sy LS, Liu IL, Bixler F, et al. Risk of herpes zoster and disseminated varicella zoster in patients taking immunosuppressant drugs at the time of zoster vaccination. Mayo Clin Proc. 2015;90(7):865–73.CrossRefPubMed
104.
go back to reference Melmed GY, Spiegel BM, Bressler B, et al. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn’s disease: 1 size does not fit all. Clin Gastroenterol Hepatol. 2010;8:655–9.CrossRefPubMed Melmed GY, Spiegel BM, Bressler B, et al. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn’s disease: 1 size does not fit all. Clin Gastroenterol Hepatol. 2010;8:655–9.CrossRefPubMed
105.
go back to reference Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterology. 2008;103:2272–80.CrossRef Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterology. 2008;103:2272–80.CrossRef
Metadata
Title
Management of Inflammatory Bowel Disease in the Elderly
Authors
Elizabeth S. John, MD
Kristina Katz, MD
Mark Saxena, MD
Sita Chokhavatia, MD
Seymour Katz, MD
Publication date
01-09-2016
Publisher
Springer US
Published in
Current Treatment Options in Gastroenterology / Issue 3/2016
Print ISSN: 1092-8472
Electronic ISSN: 1534-309X
DOI
https://doi.org/10.1007/s11938-016-0099-6

Other articles of this Issue 3/2016

Current Treatment Options in Gastroenterology 3/2016 Go to the issue

Intractable Disease in the Elderly: When Conventional Therapy Fails (S Katz, Section Editor)

Managing Esophageal Dysphagia in the Elderly

Intractable Disease in the Elderly: When Conventional Therapy Fails (S Katz, Section Editor)

Endoscopy in the Elderly: a Cautionary Approach, When to Stop

Pancreas (T Stevens, Section Editor)

Preventing Post-ERCP Pancreatitis: Update 2016

Pancreas (T Stevens, Section Editor)

Management of Disconnected Pancreatic Duct Syndrome

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine